首页 正文

Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia

{{output}}
Objective: To review the pharmacology, efficacy, and safety profile of crinecerfont as adjunctive therapy in treating classic congenital adrenal hyperplasia (CAH). ... ...